#China #Shenzhen #revenue growth #Medical Devices #LifeTech Scientific

LifeTech Scientific Reports 2025 Annual Results

LifeTech Scientific Corporation, commonly referred to as LifeTech, has recently announced their audited consolidated results for the year ending December 31, 2025. Recognized for their leading position in the medical device sector, specifically in minimally invasive interventional solutions aimed at treating cardio-cerebrovascular and peripheral vascular diseases, LifeTech has demonstrated a commendable revenue trajectory amidst challenging market dynamics.

Steady Revenue Growth

During the 2025 reporting period, LifeTech achieved approximately RMB 1,369.8 million in revenue, translating to a year-on-year growth of around 5.1%. This growth is largely attributed to a remarkable 19.9% increase in stent graft sales. As a cornerstone of their business model, LifeTech continues to carve out significant market share by enhancing its product offerings and innovating in response to clinical needs.

Strong Profitability

The company reported a gross profit of approximately RMB 1,019.1 million for the year, marking a 3.8% rise from the previous year, which results in an impressive gross profit margin of about 74.4%. In terms of net profit, after excluding non-recurring items, LifeTech noted a substantial increase of 24.9%, reaching approximately RMB 353.4 million, affirming its operational efficiency and profitability.

Robust Cash Liquidity

As of December 31, 2025, LifeTech retained a strong cash position with cash and cash equivalents totaling approximately RMB 719.3 million, an increase of 8.0% from the previous year, reflecting a well-managed balance sheet and financial stability.

Domestic and International Market Performance

LifeTech has successfully maintained a firm grip on its domestic market while simultaneously expanding its international presence. The domestic revenue growth remained stable at approximately 1.7%, accounting for about 71.1% of total revenue. On the flip side, overseas sales surged by approximately 14.4%, driven by robust demand in international markets, particularly Europe, which recorded a striking revenue growth of 25.9% and became LifeTech's largest overseas market.

Diversified Product Lines

The company's product diversification is evident across three primary business segments: Structural Heart Diseases (SHD), Peripheral Vascular Diseases (PVD), and Cardiac Pacing and Electrophysiology (CPE).

1. SHD Business: LifeTech's SHD portfolio, which includes Left Atrial Appendage (LAA) occluders, reported revenue of approximately RMB 511.7 million, despite a slight year-on-year decrease of 3.0%. The company remains committed to innovation in this area, with plans to enhance its offerings through technological advancements.

2. PVD Business: The PVD sector demonstrated solid growth, yielding about RMB 844.6 million—an increase of 12.4% year-on-year. LifeTech's comprehensive product offerings, including stent grafts and vena cava filters, cater to the rising global patient demands in vascular disease treatment.

3. CPE Business: LifeTech also leads in cardiac pacing with its robust portfolio of implantable cardiac pacemakers, contributing RMB 13.5 million in revenue.

Commitment to Research and Development

Research and development remain at the forefront of LifeTech's operational philosophy. The Group invested approximately RMB 329.0 million in R&D during 2025, equating to around 24.0% of its revenue. Key goals include fostering innovative product development, such as the Thoracoabdominal Artery Stent Graft System, which have received certifications from major regulatory bodies, strengthening LifeTech's position in the marketplace.

Strategic Collaborations

LifeTech has embarked on strategic investments, such as a partnership with Affector Medtech (Suzhou) Ltd., enhancing their presence in the growing electrophysiology sector. The investment positions LifeTech to benefit from innovative cardiac interventional products and complementary technologies.

Conclusion

According to Chairman and CEO Mr. Xie Yuehui, LifeTech has successfully navigated the challenges of 2025 while pursuing steady growth trajectories in both domestic and international arenas. LifeTech remains optimistic about leveraging its core strategies—innovation and internationalization—to further solidify its market leadership and respond to diverse clinical needs. With a well-defined growth pathway, LifeTech is set to continue making significant contributions to patient care in the medical device industry.

About LifeTech Scientific Corporation

Established in 1999, LifeTech Scientific Corporation leads the charge in developing minimally invasive medical devices. The company aims to improve patient outcomes across various cardiovascular ailments while advancing its innovative iron-based bioabsorbable material technologies. With a global reach spanning nearly 120 countries, LifeTech continues to seek new horizons for growth and innovation.